Esuprone
Based on 1 Customer Validation
Esuprone is a brain-penetrant, orally active and selective MAO A inhibitor with an IC50 of 7.3 nM. Esuprone can be used for neurological research.
For research use only. We do not sell to patients.
- Purity: 99.67%
- CAS No.: 91406-11-0
- Formula: C13H14O5S
- Molecular Weight:282.31
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
|
MAO-A 7.3 nM (IC50) |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 91406-11-0
-
Appearance Solid
-
Molecular Weight 282.31
-
Formula C13H14O5S
-
Color White to off-white
-
SMILES
CC(C1=CC=C(OS(CC)(=O)=O)C=C1O2)=C(C)C2=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 50 mg/mL (177.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Löscher W, et al. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [Content Brief]
[2]. Bergström M, et al. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur J Clin Pharmacol. 1997;52(2):121-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5422 mL | 17.7110 mL | 35.4221 mL | 88.5551 mL |
| 5 mM | 0.7084 mL | 3.5422 mL | 7.0844 mL | 17.7110 mL | |
| 10 mM | 0.3542 mL | 1.7711 mL | 3.5422 mL | 8.8555 mL | |
| 15 mM | 0.2361 mL | 1.1807 mL | 2.3615 mL | 5.9037 mL | |
| 20 mM | 0.1771 mL | 0.8856 mL | 1.7711 mL | 4.4278 mL | |
| 25 mM | 0.1417 mL | 0.7084 mL | 1.4169 mL | 3.5422 mL | |
| 30 mM | 0.1181 mL | 0.5904 mL | 1.1807 mL | 2.9518 mL | |
| 40 mM | 0.0886 mL | 0.4428 mL | 0.8856 mL | 2.2139 mL | |
| 50 mM | 0.0708 mL | 0.3542 mL | 0.7084 mL | 1.7711 mL | |
| 60 mM | 0.0590 mL | 0.2952 mL | 0.5904 mL | 1.4759 mL | |
| 80 mM | 0.0443 mL | 0.2214 mL | 0.4428 mL | 1.1069 mL | |
| 100 mM | 0.0354 mL | 0.1771 mL | 0.3542 mL | 0.8856 mL |